Royalty Pharma Q2 Adj $0.96 Misses $0.99 Estimate, Sales $537.00M Miss $628.26M Estimate
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma (NASDAQ:RPRX) reported Q2 earnings of $0.96 per share, missing the analyst estimate of $0.99. Sales were $537 million, also missing the $628.26 million estimate. Despite the misses, earnings increased by 14.29% year-over-year.
August 08, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Royalty Pharma reported Q2 earnings of $0.96 per share, missing the analyst estimate of $0.99. Sales were $537 million, also missing the $628.26 million estimate. Despite the misses, earnings increased by 14.29% year-over-year.
The earnings and sales misses are likely to negatively impact the stock price in the short term, despite the year-over-year earnings increase. Investors often react strongly to missed estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100